Forward Looking Statements

2

Forward Looking Statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of

1995, as amended. Forward-looking statements are statements that are not historical facts.

These statements

include projections and estimates and their underlying assumptions, statements regarding plans, objectives,

intentions and expectations with respect to future financial results, events, operations, services, product

development and potential, and statements regarding future performance. Forward-looking statements are

generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”

and similar

expressions.

Although Sanofi’s

management believes that the expectations reflected in such forward-looking

statements are reasonable, investors are cautioned that forward-looking information and statements are subject

to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi,

that could cause actual results and developments to differ materially from those expressed in, or implied or

projected by, the forward-looking information and statements. These risks and uncertainties include among

other

things, the uncertainties

inherent

in research

and development, future clinical

data and analysis, including

post

marketing, decisions

by regulatory

authorities, such

as the FDA or the EMA, regarding

whether

and when

to

approve

any

drug, device

or biological

application that

may

be

filed

for any

such

product

candidates as well

as

their

decisions

regarding

labelling and other

matters

that

could

affect the availability

or commercial potential

of

such

product

candidates, the absence of guarantee

that

the product

candidates if approved

will

be

commercially

successful, the future approval

and commercial success

of therapeutic

alternatives, the Group’s ability to benefit

from external growth opportunities, trends in exchange rates and

prevailing interest rates, the impact of cost

containment policies and subsequent changes thereto, the average

number of shares outstanding as well

as

those discussed or identified in the public filings with the SEC

and the AMF made by Sanofi, including those listed

under “Risk Factors”

and “Cautionary Statement Regarding Forward-Looking Statements”

in Sanofi’s

annual

report on Form 20-F for the year ended December 31, 2010.

Other than as required by applicable law, Sanofi

does not undertake any obligation to update or revise any forward-looking information or statements.

3

Agenda

3

Key Highlights on Strategy Execution

●

Christopher A. Viehbacher, Chief Executive Officer

Financial Performance

●

Jérôme

Contamine, Executive Vice President, Chief Financial Officer

Business Performance

●

Hanspeter

Spek, President, Global Operations

R&D Update

●

Dr. Elias Zerhouni, President, Global Research & Development

Conclusion

●

Christopher A. Viehbacher, Chief Executive Officer

KEY HIGHLIGHTS

ON STRATEGY EXECUTION

Christopher A. Viehbacher

Chief Executive Officer

Our Key Messages for Today

Strategy execution is on track

2011 results demonstrate importance of growth platforms

and Genzyme

acquisition

2012 is a transition year

We are set to deliver sustainable growth over 2012-2015

1

2

3

4

Executing

Successful

Strategy

to Reposition Sanofi

Deliver

sustainable growth

and generate

improved

shareholder returns

Adapt structure for future

challenges and opportunities

3

Pursue external growth

opportunities

2

Increase innovation in R&D

1

R&D Pipeline Delivery

Significantly

Improved

in 2011

Kynamro™

(mipomersen)

–

hoFH

and severe heFH

in Jul 2011 in EU

Aubagio™

(teriflunomide)

–

RMS in Aug 2011 in the U.S. and Feb 2012 in EU

Lyxumia

®

(lixisenatide)

–

Type 2 diabetes in Oct 2011 in EU

Zaltrap

®

(aflibercept)

–

2L-mCRC in Dec 2011 in EU and Feb 2012 in the U.S.

hoFH: Homozygous Familial Hypercholesterolemia heFH: Heterozygous Familial Hypercholesterolemia VTE: Venous ThromboEmbolism

RMS: Relapsing Forms of Multiple Sclerosis mCRC: MetastaticColorectal Cancer

Visamerin

®

_{/ Mulsevo}

®

_{(semuloparin)}

–

VTE prevention in chemo-treated patients in Sep 2011 in the U.S. and EU

7

Five new molecular

entities

submitted:

1

Successful

Acquisition of Genzyme

in 2011

Strong management team in place

Focus on Rare Diseases and Multiple Sclerosis

Completing the integration

Ensuring manufacturing recovery

Creating synergies

Achieved synergies of $230m in 2011

Advancing R&D pipeline

Strong Phase III results with Lemtrada

TM

Oral eliglustat

Phase III program fully recruited

Cambridge positioned as primary U.S. research site

A SANOFI COMPANY

FDA and EMA approvals granted for Framingham plant

to supply Fabrazyme

®

Progress towards focusing Allston plant on Cerezyme

®

Target inventory increase of Cerezyme

®

_{and Fabrazyme}

®

1

2

3

4

8

2

€2bn Cost

Savings

Target Achieved

in 2011

Plan

Actual

Plan

Actual

Plan

Revised

€2bn

€1.3bn

€0.5bn

2009

2010

2011

(1) At CER, before inflation and tax on a constant structure basis compared to 2008

(2) Not including Industrial Affairs net savings evaluated at €200m

OpEx Savings

(1,2)

New plan to generate €2bn incremental cost savings by 2015

9

Sanofi Grew

Sales in 2011

due to Genzyme

Acquisition

and Growth

Platforms

2011

€33,389m

2010

€32,367m

2009

€29,306m

2008

€27,568m

Sales

+5.3

%

at CER

10 (1) In 2008 and 2009, Merial Joint Venture sales were not consolidated by Sanofi

(2) In 2010, excluding non-consolidated sales from Merial, Sanofi reported sales of €30,384m

2009

2010

2011

2008

% of

Total

42.7%

65.0%

Sales of

Growth Platforms

(1)

_{& Genzyme}

Sanofi Boosted Sales of its Growth Platforms and

Significantly Reduced its Patent Cliff Exposure in 2011

(1) 2010 include sales of Merial. In 2008 and 2009, Merial JointVenture sales were not consolidated by Sanofi

(2) Lovenox®_{U.S., Plavix}®_{Western EU, Taxotere}®_{Western EU & U.S., Eloxatin}®_{U.S., Ambien CR}®_{U.S., Allegra}®_{U.S., Aprovel}®_{Western EU,}

Xyzal®_{U.S., Xatral}®_{U.S., Nasacort}®_{U.S. -Generic makers of oxaliplatin required to cease selling in the U.S. since June 30, 2010 but judgement is}

under appeal by Sun.

2011

2009

2010

2008

11

% of

Total

27.4%

9.4%

Sales of

Key Genericized Products

(2)

€21,703m

€11,783m

€3,152m

12

2011

2008

€3,071m

Diabetes

Solutions

2011

2008

€6,540m

Emerging

Markets

(1)

2011

2008

€2,861m

Human

Vaccines

2011

2008

€1,203m

Consumer

Health Care

2011

2008

Animal

Health

(2)

2011

2008

Innovative

Products

(3)

€1,786m

Growth Platforms

Are on Track to Deliver Sustainable

Growth Beyond the Patent Cliff

(1) Including €347m from Genzyme in 2011

(2) Merial Joint Venture sales were not consolidated by Sanofi in 2008

(3) Multaq®_{and Jevtana}®

€10,133m

€4,684m

€3,469m

€2,666m

€2,030m

€449m

CAGR +15.7% CAGR +15.1% CAGR +6.6% CAGR +30.4% CAGR +4.4%

Geographic Sales Split Balanced in 2011

13

Note: Sales growth excluding A/H1N1 and Genzyme is : -5.7% for U.S., -10.5% for Western Europe, +10.4% for Emerging Markets, +6.3% for ROW

(1)World less North America (USA, Canada), Western Europe (France,Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Holland, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New Zealand

(2)Japan, Canada, Australia and New Zealand

ROW

€4,169m

+13.8% at CER

12.5%

United

States

€9,957m

+6.8% at CER

29.8%

Western

Europe

€9,130m

-4.0% at CER

27.3%

Emerging

Markets

€10,133m

+10.1% at CER

30.3%

(1) (2)

€6.61

2011

€6.65

2010

€7.06

2009

2008

€5.59

Patent Cliff Impact on EPS Mitigated in 2011

Business EPS

14

-3.8%

2013e

2011

€2.65

2010

€2.50

2008

€2.20

2009

€2.40

15

Sanofi Increases Shareholder Returns

●

Proposed dividend

(1)

_{of €2.65}

per share for 2011 results

●

Progressive increase of

payout target to 50% for

2013 results

(2)

●

Over €1bn of shares

repurchased during 2011

●

Opportunistic share

repurchase program

during 2012

Evolution of Dividend

Payout

40%

Payout

50%

(1) To be submitted for approval by the Shareholders’Annual General Meeting on May 4, 2012

(2) Dividend to be paid in 2014

+6%

Payout

35%

FINANCIAL PERFORMANCE

Jérôme Contamine

Executive Vice President, Chief Financial Officer

+€2,569m

Growth

Platforms

+€1,943m

Others

-€128m

A/H1N1

-€452m

Key

Genericized

Products

-€2,206m

FY 2010

€32,367m

FY 2011

€33,389m

FX Impact

-€704m

Genzyme

Genzyme and Growth Platforms Overcome Loss of

Blockbusters in 2011

17

(1) Lovenox®_{U.S., Plavix}®_{Western EU, Taxotere}®_{Western EU & U.S., Eloxatin}®_{U.S., Ambien CR}®_{U.S., Allegra}®_{U.S., Aprovel}®_{Western EU, Xyzal}®_U.S.,

Xatral®_{U.S., Nasacort}®_{U.S. -Generic makers of oxaliplatin required to cease selling in the U.S. since June 30, 2010 but judgement is under appeal by Sun.}

(2) Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care, Innovative Products & Animal Health (3) Consolidated since April 1st_{, 2011}

FY 2011 Sales (€m)

(1)

(2)

The US$ Remained our Biggest Currency in 2011

18

2011 Currency Sales Exposure

Euro €

29.6%

U.S. $

28.2%

Japanese ¥

8.4%

Brazilian Real

4.4%

Chinese Yuan

3.1%

Australian $

2.3%

Russian Ruble

2.2%

British £

2.0%

Canadian $

1.6%

€

/ U.S. $ sensitivity

estimated at 0.3%

of 2012 EPS growth

for a 1-cent movement

19

Sales and Business EPS Up +9.2% at CER in Q4 2011

€m

Q4 2011

Q4 2010

% Change

(reported €)

% Change

(CER)

Net sales

8,508

7,823

+8.8%

+9.2%

Other revenues

415

419

-1.0%

-1.9%

Gross profit

6,202

5,770

+7.5%

+7.3%

Business operating income

2,828

2,540

+11.3%

+10.0%

Business net income

2,077

1,838

+13.0%

+11.7%

Business EPS

€1.56

€1.41

+10.6%

+9.2%

20

FY 2011 P&L Reflects Genzyme Consolidation

and Shift in Business Mix

€m

FY 2011

FY 2010

% Change

_{(reported €)}

% Change

_(CER)

Net sales

33,389

32,367

+3.2%

+5.3%

Other revenues

1,669

1,669

0.0%

+4.0%

Cost of sales

(10,426)

(9,302)

+12.1%

+14.3%

Gross profit

24,632

24,734

-0.4%

+1.9%

R&D

(4,811)

(4,556)

+5.6%

+7.4%

SG&A

(8,536)

(8,171)

+4.5%

+6.7%

Other current operating income & expenses

4

77

-

-Share of Profit/Loss of associates

1,102

1,036

-

-Minority interests

(247)

(257)

-

-Business operating income

12,144

12,863

-5.6%

-3.9%

Business operating margin

36.4%

39.7%

-

21

Cost of Sales of 31.2% in 2011 In-Line with Guidance

Cost of Sales (%)

31.6%

32.0%

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

●

Higher Cost of Sales in 2011

vs. 2010 as anticipated due to:

●

Loss of sales of €2,206m from

key genericized products with

relatively low Cost of Sales

●

Lack of A/H1N1 sales

●

Productivity improvements

●

Decrease of CoGS ratio excluding

key genericized products and

A/H1N1

(1)

21

31.2%

28.8%

(1) Lovenox®_{U.S., Plavix}®_{Western EU, Taxotere}®_{Western EU & U.S., Eloxatin}®_{U.S., Ambien CR}®_U.S.,

Allegra®_{U.S., Aprovel}®_{Western EU, Xyzal}®_{U.S., Xatral}®_{U.S., Nasacort}®_{U.S. -Generic makers of oxaliplatin}

required to cease selling in the U.S. since June 30, 2010 but judgement is under appeal by Sun.

14.9%

15.2%

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

14.4%

14.1%

22

Tight Control over R&D Expenditures in 2011

●

2011 R&D expenses of €4,811m,

up 7.4% at CER

●

Addition of €419m of R&D

expenses from Genzyme

●

R&D/Sales ratio slightly up vs.

2010 to 14.4%

●

R&D expenses down 2.4% at CER

excluding Genzyme reflecting

transforming initiatives

22

R&D/Sales Ratio (%)

28.1%

26.1%

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

2010

2011

25.6%

25.2%

23

SG&A Expenses Excluding Genzyme

Declined in 2011

SG&A/Sales Ratio (%)

●

2011 SG&A expenses of €8,536m,

up +6.7% at CER

●

SG&A expenses down 2.6% when

excluding Genzyme

●

SG&A/Sales ratio only slightly up

in 2011 vs. last year reflecting:

●

Lower ratio of Selling & Marketing

Expenses to Sales ratio

●

Genzyme consolidation

●

Lower SG&A ratio in Q4 reflecting

tight control of SG&A expense and

start of Genzyme synergies

24

€m

FY 2011

FY 2010

% Change

(reported €)

% Change

(CER)

Business operating income

12,144

12,863

-5.6%

-3.9%

Net financial expenses

(412)

(362)

-

-Income tax expense

(2,937)

(3,286)

-

-Effective tax rate

-27.0%

-28.0%

-

-Business net income

8,795

9,215

-4.6%

-2.7%

Net margin

26.3%

28.5%

-

-Business EPS

€6.65

€7.06

-5.8%

-3.8%

Average number of shares outstanding (in million)

1,321.7

1,305.3

-

-Patent Cliff Impact on BNI Largely Mitigated in 2011

CER: Constant Exchange Rates

From Business Net Income to Consolidated Net Income

€m

2011

2010

% Change

_{(reported €)}

Business net income

8,795

9,215

-4.6%

Amortization of intangible assets

(3,314)

(3,529)

Impairment of intangible assets

(142)

(433)

Fair value remeasurement of contingent consideration liabilities

15

Expenses arising on the workdown of acquired inventories

(476)

(142)

Restructuring costs

(1,314)

(1,384)

Gains and losses on disposals, and litigation

(327)

(138)

Discontinuation of depreciation of PP&E (IFRS5)

77

Tax effect on the items listed above &

other tax items

2,482

1,856

Share of items listed above attributable to

non-controlling interests

6

3

Restructuring costs and expenses arising from the impact of

acquisitions on associates and Merial

(32)

(58)

Net income attributable to equity holders of Sanofi

5,693

5,467

+4.1%

Restructuring Costs & Others

-977

Dividend & Share Repurchase

-2,446

Acquisitions & Licensing

-14,217

CapEx

-1,644

Net Cash from Operating Activities

+10,002

Net Debt Dec 31, 2011 Net Debt Dec 31, 2010 26

Strong Free Cash Flow Generated in 2011

+ €2,016m

(1) Excluding Restructuring Costs

(2) Including -€754m Fx translation effect on Net Debt vs. end of Dec 2010

(1) (2)

●

Continued strong Free Cash

Flow of €8,358m

●

Stable operating cash flow

of €10,478m

●

CapEx limited to €1,644m

despite inclusion of CapEx

from Genzyme and Merial

●

Net debt below 1X EBITDA

●

Reasonable leverage

●

Low average cost of gross

debt of 2.6% in 2011

In €m

-1,577

-10,859

FCF

8,358

27

CoGS

:

Increase productivity through Total Cost

Ownership and LEAN approaches

R&D:

Restructure footprint and variabilize costs

(1)

Commercial Operations:

Optimize field forces and marketing spend

Support Functions:

Leverage shared services model

(1) 2011 R&D expenses on a proforma basis should reach around €5bn

(2) At CER, before inflation and tax on a constant structure basis

New Initiatives Combined with Genzyme Synergies

to Generate Incremental Cost Savings of €2bn by 2015

Genzyme:

Simplify organization and leverage

Sanofi infrastructure

Cost

savings

of

BUSINESS PERFORMANCE

28

Hanspeter Spek

29

Growth Platforms

(1)

+ €1,943m

Emerging Markets:

+ €962m

(3)

Diabetes Solutions:

+ €516m

CHC: +

€505m

Vaccines w/o A/H1N1

(4)

_{: +}

_€242m

Innovative Products: +€208m

Animal Health:

+ €85m

+ €2,569m

(5)

Key Genericized Products

(2)

Taxotere

®

_{U.S. & Western EU:}

_{- €1,066m}

Lovenox

®

_{U.S.: - €781m}

Ambien

®

_{U.S.: - €357m}

Plavix

®

_{Western EU:}

_{- €180m}

Allegra

®

_{U.S.: - €144m}

Xyzal

®

_{U.S.: - €114m}

Others

(2)

_{: - €240m}

Total - €2,882m

Eloxatin

®

_{U.S.: +}

_€676m

(6)

Group Sales

€33,389m

+5.3%

at CER

Growth Platforms & Genzyme Lead to Sales Growth

in 2011 despite Generic Competition

(1) Growth platforms: Emerging Markets, Diabetes Solutions, Vaccinesexcluding A/H1N1, CHC, Innovative Products (Multaq®_{and Jevtana}®_{), Animal Health}

(2) Other key genericized products include Aprovel®_{in Western EU, Nasacort}®_{and Xatral}®_{in the U.S.}

(3) Incremental quarterly sales contribution from Emerging Markets excluding other Growth Platforms and Genzyme was €148m

(4) A/H1N1 vaccine sales were €452m in 2010

(5) Genzyme 2011 sales at 2010 exchange rates

(6) Eloxatin®_{U.S. market exclusivity expected through August 9, 2012}

2011 Sales Change (€m)

Growth Platforms Delivered Double-Digit Sales Growth

in 2011

30

Emerging Markets

Consumer Health Care

Vaccines

Animal Health

Innovative Products

(4)

Diabetes Solutions

€10,133m

+10.4%

+10.4%

€3,469m

+7.2%

+7.2%

€4,684m

+12.0%

+12.0%

€2,666m

+22.8%

+22.8%

€2,030m

+4.3%

+4.3%

excluding Genzyme & A/H1N1(2)

excluding A/H1N1(3)

€449m

n/a

n/a

Growth is at CER (Constant Exchange Rates)

(1) 2011 Growth Platforms and Genzyme sales increased by +21.7% atCER including €452m of A/H1N1 vaccine sales in 2010 and €2,395m of Genzyme sales in 2011

(2) 2011 Emerging Markets sales increased by +10.1% at CER including€361m of A/H1N1 vaccine sales in 2010 and €347m of Genzyme sales in 2011

(3) 2011 Vaccines sales decreased by -5.5% at CER when including €452m of A/H1N1 vaccine sales in 2010

(4) Multaq®_{and Jevtana}®

Growth Platforms

€19,308m

excluding Genzyme & A/H1N1(1)

+10.8%

+10.8%

31

Aprovel

®

_EU

Key Genericized Products

(1)

Quarterly Sales (€m)

(1)Key genericized products include Lovenox®_{U.S., Plavix}®_{Western EU, Taxotere}®_{Western EU & U.S., Eloxatin}®_{U.S., Ambien CR}®_{U.S., Allegra}®

U.S., Aprovel®_{Western EU, Xyzal}®_{U.S., Xatral}®_{U.S., Nasacort}®_{U.S. -Generic makers of oxaliplatin required to cease selling in the U.S. since June 30,}

2010 but judgement is under appeal by Sun.

(2) Eloxatin®_{U.S. market exclusivity expected through August 9, 2012.}

Patent Cliff Declined Further in Q4 2011 despite Recovery

of U.S.

Eloxatin

®

_Sales

€744m

€773m

€945m

€1,072m

Q4 2010

Q1 2011

Q2 2011

Q3 2011

Q4 2011

€690m

% of Total Sales

13.7%

12.1%

9.3%

8.1%

Eloxatin

®

_{U.S.: €260m}

(2)

Lovenox

®

_U.S.

Plavix

®

_EU

€430m

Others

8.5%

32

Emerging Markets Grew at Double-Digit Organic Rate

in 2011

(1)World less North America (USA, Canada), Western Europe (France,Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Holland, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New Zealand

(2)Growth is at CER. Merial sales consolidated from 2010 (€1,983m in 2010). A/H1N1 sales in Emerging Markets were €361m in 2010. Genzyme sales in Emerging Markets were €347m in 2011.

+16%

+9%

2011

€10.1bn

2010

2009

2008

2007

2006

2005

€5.0bn

Emerging Markets Sales

●

Record Emerging Markets

(1)

sales of €10,133m in 2011

●

+10.1% at CER

●

+10.4%

excluding Genzyme

and A/H1N1 sales

(2)

●

30.3% of Group sales

●

Strong sales in BRIC of €3,467m

●

+14.9% at CER

●

+19.8%

excluding Genzyme

33 (1)World less North America (USA, Canada), Western Europe (France,Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg,

Portugal, Holland, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New Zealand

(2)Genzyme sales in Emerging Markets were €115m in Q4 2011

(3)Growth at CER excluding A/H1N1 vaccines and Genzyme

Acceleration in Emerging Markets in Q4 2011 Driven by

Strong Performance in LatAm and Asia

●

Q4 2011 Emerging Markets

(1)

_{sales of €2,649m}

●

Growth of +13.8% at CER without Genzyme or +18.7% at CER with Genzyme

(2)

Emerging Markets Q4 2011 Sales Split

(3)

€476m

€634m

€667m

€827m

Latin

America

Eastern

Europe &

Turkey

Asia

Africa &

Middle East

+21.0%

+4.9%

_+15.6%

+9.8%

33

Other Emerging Markets

+10.6%

BRIC

(Brazil, Russia, India, China)

+20.2%

Q4 2011 Growth Rates

34

+17.8%

+14.6%

+14.5%

+13.2%

Q1 2011

Q2 2011

Q3 2011

Q4 2011

Diabetes Shows Impressive Double Digit Sales Growth

in all Four Quarters of 2011

Quarterly Sales (€m)

(1)

€1,054m

(1) Growth at CER (Constant Exchange Rate)

●

Strong performance of Diabetes

with 2011 sales of €4,684m, up

+12.0% at CER

●

Lantus

®

_{2011 sales of €3,916m,}

+15.0% at CER

●

Lantus

®

_{quarterly sales >€1bn for the}

first time

●

Growth of +16.7% in the U.S. related

to increased market penetration of

SoloSTAR

®

_(50%)

●

Strong Emerging Markets sales up

+30.7%

●

Nordic study confirms Sanofi’s

confidence in the safety of Lantus

®

35

Robust CHC Growth Boosted by Allegra

®

_{Launch in 2011}

(1) Growth at constant perimeter and exchange rate for FY 2011: +14.1%

(2) Internal estimate based on Nicholas Hall dB6 OTC database

(3) A.C. Nielsen Food, Drug and Mass excluding Walmart (represents 64% of all outlets) 13-week period ending December 24, 2011

€1,203m

€1,430m

€2,217m

€2,666m

FY 2008

FY 2009

FY 2010

FY 2011

Annual Sales (€m)

●

Record 2011 CHC sales of

€2,666m, +22.8%

(1)

_{at CER}

●

Sanofi now among Top 5 OTC

companies globally

(2)

●

Allegra

®

_{: most successful OTC}

launch in the U.S. in 2011 with

sales of €211m

●

#2 brand in the category

(3)

●

#1 OTC brand for Sanofi globally

●

Investing in the dynamic CHC

market in China (BMP Sunstone)

and India (Universal Medicare)

+22.8%

36

Becoming a Significant Regional Player in Generics

(1) Gx organic growth is +14.6% in FY 2011

Annual Sales (€m)

●

Solid 2011 sales of €1,746m,

up +16.2%

(1)

_{at CER}

●

Strong Q4: €488m, +21.0% at CER

●

AGx of Lovenox

®

_{available in the}

U.S. market

●

Over €1bn of sales in Emerging

Markets in 2011

(62.5% of Gx sales)

●

+14.0% in Emerging Markets

●

Roll-out of Medley in LatAm

2009

2010

2011

U.S.

Emerging

Markets

Western

Europe

Others

€1,746m

€1,534m

€1,012m

2011 Sales Split by Region

37

Merial Showed Strong Resilience in 2011 despite

Competitive Challenges

(1) Positive U.S. court ruling barring further sales of Cipla and Velcera’s generics and ordering seizure of U.S. inventory in possession of generic makers on August 21, 2011

●

2011 sales of €2,030m, up +4.3%

at CER

●

Companion Animals segment sales of

€1,277m, +1.8% despite temporary

U.S. generic competitor of Frontline

®

Plus

(1)

_{and new U.S. competitor}

●

Solid Production Animals segment

sales of €753m, +8.9% at CER

●

Acceleration of Emerging Markets

sales up +12.4% at CER to €507m

●

Rebound in Q4 with sales of

€470m, up +10.0% at CER

●

Recovery of Frontline

®

_Plus

(1)

●

Increased uptake of Certifect

®

in the U.S.

40%

U.S.

27%

Western

Europe

Emerging

Markets

Other

Countries

25%

8%

Vaccine Sales Driven by Growth in Emerging Markets

and Sustained Performance in Mature Markets in 2011

38

(1) FY 2011 sales down -5.5% including A/H1N1

●

FY 2011 sales: €3,469m, +7.2%

excluding A/H1N1

(1)

●

Record year for flu (€826m, +2.5%)

supported by differentiation strategy

●

Emerging Markets up +10.7%

excluding A/H1N1

●

Solid Q4 excluding influenza

●

Strong Pentaxim

®

_{in Emerging}

Markets and Adacel

®

_globally

●

Menactra

®

_{(€93m, +43.2%) driven}

by booster recommendations in

U.S. and global launches

●

Q4 flu sales reflect early shipments

of Fluzone

®

_{in the U.S.}

2011

€3,469m

2010

€3,808m

Seasonal Influenza

Pandemic

Other

Meningitis/Pneumo

Travel/Endemic

Adult Boosters

Polio/Pertussis/Hib

FY 2011 Sales

+7.2%

excluding

A/H1N1

-5.5%

including

A/H1N1

39

Q2 2011

Q3 2011

Q4 2011

Genzyme Recovery On Track

Quarterly Sales

(1)

_(€m)

&

●

FY 2011 Genzyme consolidated

sales reached €2,395m, +7.7%

(1,2)

●

Q4 2011 sales of €831m, +0.8%

(2)

●

Rare Diseases sales of €346m

•

Solid performance of Myozyme

®

_/

Lumizyme

®

_{of €108m, +15.9%}

•

Cerezyme

®

_{and Fabrazyme}

®

_sales

constrained by supply

●

Good performance of Renagel

®

_/

Renvela

®

_{and Synvisc}

®

_franchise

●

EMA and FDA approvals granted

for Framingham plant in Jan 2012

●

Complete return to normal supply

levels of Fabrazyme

®

_{to begin in}

Q2 2012

&

_Other

s

(1) Genzyme sales are consolidated since April 1, 2011

(2) Change on a constant structure basis and at constant exchange rates

€796m

€768m

€831m

R&D UPDATE

40

Dr. Elias Zerhouni

Executing our R&D Strategy

Global

R&D

Goals

An efficient global R&D organization

Maximize synergies and convergence around Hub model

Exploit economies of scale

Improve R&D cost structure

Focus on high-value projects

Execute on late-stage projects

Medical value and translational feasibility to guide early-stage

portfolio prioritization

Establish new models of external innovation

Enhance the value of external opportunities and partnerships

Create open and creative model of pharma-biotech partnership

e.g. Warp Drive Bio

Focusing on Delivering a Promising Development Portfolio

Achieve Regulatory Milestones

•

Lemtrada™

•

Aubagio™

•

Lyxumia

® (1)

•

Zaltrap

® (2)

•

Visamerin

®

•

Kynamro™

(3)

Fastrack Next Wave of Late-Stage Projects

•

New glargine formulation

•

Glargine-lixisenatide combo

•

Dengue vaccine

•

Eliglustat

•

Anti-PCSK-9 mAb



EU/U.S.



EU



EU/U.S.



EU/U.S.



EU

•

Otamixaban

•

Sarilumab

•

JAK-2 inhibitor

•

Iniparib

•

Ombrabulin

Short-term

opportunities

Mid-term

opportunities

Submitted

42

Lemtrada™, Aubagio™, Lyxumia®_{, Zaltrap}®_,Visamerin®_{and Kynamro™ are registered trade names submitted to health authorities for investigational agents}

(1) In-licensed from Zealand Pharma A/S (2) Partnership with Regeneron (3) In-licensed from Isis Pharmaceuticals

Unmet need 3

Efficacy with

manageable safety

Unmet need 2

Convenience

&

efficacy

Early MS/CIS

(1)

RRMS

(2)

and

early active MS

RMS

(3)

_severe/

highly active

Emergence of a Franchise Addressing the Full Spectrum

of Patient Needs in Multiple Sclerosis

Lemtrada

™

43

Aubagio

®

Unmet need 1

Convenience

&

safety

Rebif

®

Lemtrada

™

Aubagio

™

CIS –Clinically Isolated Syndrome, TOPIC Phase III study presently ongoing RRMS –Relapse Remitting Multiple Sclerosis

RMS –Relapsing Multiple Sclerosis

Genzyme -

MS

A Unique Value Proposition: Superior Efficacy

with Convenient Annual Dosing

CARE-MS I

CARE-MS II

Patients

581

840

Study Duration

2 years

2 years

Patient

Population

Treatment

naïve

Relapsed on

prior treatment

Treatment

Arms

Alemtuzumab

vs. IFN

β

1a

Alemtuzumab

vs. IFN

β

1a

Relapse Rate Reduction

at 2 Years

(1)

55%

(p<0.0001)

49%

(p<0.0001)

Sustained Accumulation

of Disability Reduction in

6 Months

(1)

30%

(ns)

42%

(p=0.0084)

●

Superior efficacy demonstrated

in Phase III vs. Rebif

®

●

Manageable safety:

●

Well-characterized and consistent

across studies

●

Effective risk management

procedures in place

●

FDA Fast Track designation

granted

(1) Co-primary endpoints in CARE-MS I and CARE-MS II 44

45

Aubagi A Once-Daily Oral Therapy with

Comparable Efficacy to Injectable Interferon

●

Efficacy demonstrated in TEMSO

on both Relapse Rate and

Disability Progression at 14mg

●

No superiority vs. Rebif

®

_in

TENERE but lower rate of

TEAE-related discontinuation

●

Manageable safety

with up to 10

years of follow-up

(1) Adjusted for Expanded Disability Status Scale score strata at baseline and takes duration of treatment into account. TEAE – Treatment Emergent Adverse Events,

ARR –Annualized Relapse Rate, RRR –Relative risk reduction, HRR –Hazard ratio reduction

0

0,1

0,2

0,3

0,4

0,5

0,6

T. 14 mg

T. 7 mg

Placebo

TEMSO: Reduction in Adjusted

(1)

_ARR

RRR: 31.2%

p=0.0002

RRR: 31.5%

p=0.0005

0

12

24

36

48

60

72

84

96

108

0%

20%

10%

HRR: 23.7%

p=ns

HRR: 29.8%

p=0.0279

30%

Placebo

T. 7 mg

T. 14 mg

Week

TEMSO: Reduction in Disability Progression (%)

A GLP-1 Agonist with Unique Post-Prandial

Effect and One Step Titration

Mono

Mono Japan

Drug naïve patients

Placebo-controlled

in OAD failure

M (metformin)

F1 (metformin)

M Asia (metformin)

S (sulfonylurea)

P (pioglitazone)

X vs. exenatide

Active-controlled

L

L Asia

Placebo-controlled on

top of basal insulin

Placebo-controlled

Secondary prevention

Cardiovascular

Outcomes Study









Reported

Lixisenatide was in-licensed from Zealand Pharma A/S.

Lyxumia®_{is the intended trademark for lixisenatide. Lixisenatide is currently not approved or licensed anywhere in the world. 46}







Duo 1 (Lantus

®

₎







Consistent GLP-1 class effects

of A1c reduction and weight loss



Pronounced effect on

post-prandial glucose



Favorable safety profile with low

risk of hypoglycemic events



OD injection, simple 1 step

to maintenance dose, 1 pen

per dose

Lyxumia

®

_Profile

®

Diabetes

●

3 positive GetGoal trials with

Lyxumia

®

_{on top of basal}

insulin

●

A1c target and PPG control

achieved when used on top of

Lantus

®

_{in GetGoal-Duo 1}

(3)

●

Development of injection device

for variable Lantus

®

_{dose with}

fixed Lyxumia

®

_{dose on track}

for Phase III initiation early

2013

T2D Patients Treated with Basal Insulin

(1)

(worldwide)

On basal insulin

On basal insulin

with controlled fasting

glucose control

but A1c >7%

4 million

on other

basal insulins

(2)

4 million

on Lantus

®

4 million

T2D –Type 2 Diabetes, A1C –Glycated hemoglobin, PPG –Post Prandial Glucose

(1)Adapted from IMS data

(2)Includes all types of basal insulins

(3)Top line results press release (6 Dec 2011) –Full results expected at a forthcoming scientific meeting

Optimal Complementary Pharmacological

Profile with Basal Insulins

Diabetes

®

New Glargine Formulation with Unique Pharmacokinetics

48

New Insulin Glargine Formulation

Depot formation after subcutaneous injection

PK/PD: Pharmacokinetic/pharmacodynamic T2D: Type 2 Diabetes

Schematic illustration

●

New glargine formulation

provides

●

Unique flat PK/PD profile

●

Lower injection volume

●

Phase III trials recently initiated

in T2D high dose insulin users

●

Targeting ~1,600 patients

Diabetes

Lantus

®

New Glargine

Strenghtening our Portfolio of Oncology Drugs

49

●

A novel VEGF trap acting on

multiple angiogenic targets

●

Previously treated metastatic

colorectal cancer

●

VELOUR: Significant improvement

in Overall Survival

●

Manageable safety profile

consistent with previous studies

Zaltrap

®

_aflibercept

NSCLC –Non Small Cell Lung Cancer

VTE –Venous Thrombo Embolism (includes Deep Venous Thrombosis and Pulmonary Embolism)

Oncology

●

Only ultra-LMWH effective in

reducing VTE risk reduction in

chemo-treated cancer patients

●

Without impact on major bleeding

incidence

●

Treatment effect consistent

across solid tumor types, stages

and geographical regions

Kynamro™: Targeting Rare Familial

Hypercholesterolemias

50

(1) Patients for hoFH and Severe FH in US and EU markets hoFH –Homozygous Familial Hypercholesterolemia

Severe FH –Severe Familial Hypercholesterolemia = treated LDL-C CHD –Coronary Heart Disease heFH –Heterozygous familial hypercholesterolemia

●

Four Phase III trials conducted in

severe FH forms

●

Significant reduction in LDL-C when

added to a regimen of maximally

tolerated statin dose and other lipid

lowering therapies

●

Liver fat stabilized or decreased

in some patients with treatment

beyond 12 months

●

Sustained reduction in apo B

production decreased LDL

and Lp(a)

HeFH:

1 million

patients

HoFH

Severe FH

Understanding Rarity

~40,000 patients

(1)

On statins:

60 million

patients

PCSK9 mAb: a First in Class Addressing Unmet Needs

in Hypercholesterolemias

51

LDL-C Dose Response (Phase Ib)

Atorvastatin Combo-Rx, heFH & Non-FH Combined

Mean Percent Change from Baseline

in Calculated LDL-C (%)

= Dose administered

Placebo

50 mg

100 mg

150 mg

CHD –Coronary Heart Disease, heFH –Heterozygous familial hypercholesterolemia , ACC –American College of Cardiology

(1)Cohen JC. N Engl J Med 2006;354(12):1264-72

●

Landmark study demonstrated that

when PCSK9 is disabled,

cholesterol and risk of CHD are

greatly lowered

(1)

●

Preliminary Phase II data

●

>65% LDL-C reduction in FH and

primary hypercholesterolemia on

top of baseline statin use

●

Generally safe and well tolerated

●

Phase III targeted to start Q2 2012

G. Swergold et al. Circulation 2011; 124: A16265

Metabolic Disorders

Otamixaban: Providing Superior Outcomes while

Simplifying Treatment during Interventional Procedures

●

Despite current therapies, death, MI,

and readmission rates remain high

●

Otamixaban is the first IV direct and

selective factor Xa inhibitor with

quick onset/offset

●

27 to 42% risk reduction in ACS

complications including death and

MI in Phase Il

(1)

●

Phase III TAO study ongoing and

expected to complete by end 2012

(1) The Lancet, Volume 374, Issue 9692, Pages 762 -764, 5 September 2009

NSTE-ACS –Non-ST-Elevation Acute Coronary Syndrome, MI –Myocardial Infarction, UFH –Unfractionated Heparin

TAO Study

Moderate-to-high risk NSTE-ACS with

planned early invasive strategy

(n=13,220)

Primary endpoint:

Death/Myocardial Infarction @ day 7

Otamixaban

Regimen 2

(n=1,969)

Otamixaban

Regimen 1

(n=1,969)

UFH +

Eptifibatide

(n=1,969)

R

Thrombosis

52 Sponsor-blinded interim analysis

Eliglustat: a Novel Oral Therapy in Gaucher Disease

(1)

●

Potent, novel substrate inhibitor

●

Convenience of oral therapy

●

Eliminating challenges of

infusing patients

●

Clinical profile expected to be

similar to Cerezyme

®

●

4-year Phase II data at WORLD

congress in February 2012

●

Phase III trials fully recruited

53

(1) Investigational drug

(2) Patient from Phase II clinical trial

WORLD –World Organization of Research on Lysosomal Diseases

Genzyme -

Rare Diseases

December 2006

pre-treatment (18 years)

December 2009

54

Dengue Vaccine: Addressing a Growing Global Threat

Ambitious R&D Program

●

Global Phase III program

(43,000 individuals)

●

1

st

_{efficacy results expected}

by end of 2012

●

First submissions planned

in 2013

Significant Disease Burden

●

Estimated 220m dengue

infections worldwide per year

●

2m cases of Hemorrhagic

Fever

●

>500,000 hospitalizations and

>20,000 deaths / year

●

Dengue: a public health

priority in Asia and Latin

America

Vaccines

Rare Diseases & MS

Diabetes

Oncology

Other Pharma

Ophthalmology

Vaccines

Eighteen Potential New Launches over 2012-2015

5

8

Kynamro™

(mipomersen)

14

18

Lemtrada™

(alemtuzumab)

Aubagio™

(teriflunomide)

Lyxumia

®

(lixisenatide)

Zaltrap

®

(aflibercept)

Visamerin

®

(semuloparin)

Hexaxim

®

ombrabulin

Dengue vaccine

eliglustat

SAR302503

(JAK-2 inhibitor)

otamixaban

DTP-HepB-

Polio-Hib

FOV1101

(prednisporin)

SAR236553

anti-PCSK-9 mAb

iniparib

2012

2013

2014

2015

Cumulative Number of Projects

Pharmaceuticals (excluding LCM) and Vaccines

Fluzone

®

_{QIV IM}

Quadracel

®

Note: Scope includes pharmaceuticals NMEs (excluding LCM –Life cycle management) and vaccines. Only first launches in a given market are mentioned.

hoFH–Homozygous Familial Hypercholesterolemia m-CRC –Metastatic Colorectal Cancer

RMS –Relapsing forms of Multiple Sclerosis

Multiple Important Catalysts in 2012

56 Zaltrap®_{, Lemtrada™, Aubagio™ and Kynamro™ are}

registered trade names submitted to health authorities for investigational agents

2012

Expected Regulatory Submissions

Q1

Q2

Q3

Q4

●

Kynamro™

(mipomersen) in hoFH in the U.S.



●

Lemtrada™

(alemtuzumab) in RMS in the U.S. and EU



●

Lyxumia

®

(lixisenatide) in Type 2 diabetes in the U.S.



Expected Headline Data Releases

●

Zaltrap

®

(aflibercept) -

Phase III results in 1

st

line prostate cancer (VENICE)



●

Aubagio™

(teriflunomide) -

Phase III results in RMS (TOWER)



●

Lantus

®

-

Phase III results in reduction in CV morbidity & mortality (ORIGIN)



●

Otamixaban

-

Phase III study completion in ACS



Expected Phase III Study Initiations

●

New insulin glargine formulation

-

Phase III in diabetes (EDITION)

CONCLUSION

Christopher A. Viehbacher

Chief Executive Officer

2012 Is a Transition Year for Sanofi

58 (1)Avapro®_{U.S. patent expiry on March 30, 2012, Plavix}®_{U.S. paediatric exclusivity expiry in May 17, 2012}

and Eloxatin®_{loss of exclusivity expected on August 9, 2012 58}

Tailwinds

●

Performance of our growth

platforms

●

Benefit of Genzyme consolidation

for one additional quarter

(Q1 2012)

●

Continued discipline on costs

●

Expected U.S. generic competition

for Avapro

®

_{, Plavix}

®

_and

Eloxatin

®(1)

●

Full-year impact of Taxotere

®

generic

●

U.S. launch of 2

nd

_enoxaparin

generic

●

Copaxone

®

_{agreement terminating}

in early Q1 2012

EPS Guidance for FY 2012

2012 Will Be a Turning Point towards Sustainable Growth

59 (1) Avapro®_{U.S. patent expiry on March 30, 2012, Plavix}®_{U.S. paediatric exclusivity expiry in May 17, 2012}

(2) Growth is at CER (Constant Exchange Rates)

(3) FY 2011 Business EPS: €6.65 59

●

As announced last September, the loss of Plavix

®

_{and Avapro}

®

exclusivity in the U.S. is anticipated to impact the 2012 business net

income by around €1.4 billion at CER

(1)

●

Taking into account this impact, the performance of growth platforms,

contribution from Genzyme and cost control as well as other generic

competition should lead to a 2012 business EPS

12% to 15% lower

than 2011 at CER

, barring major unforeseen adverse events

(2,3)

Continued Execution of Strategy Expected to Deliver

Sustainable Growth 2012-2015

2012-2015 Sales CAGR

Diversified sources of growth

Scale in businesses with significant barriers to entry

Low small molecule patent exposure in mature markets

(1)

Large Emerging Markets presence

(2)

Potential new product launches

(3)

Operating margin evolution

2012-2015 Business EPS CAGR

Increased dividend payout ratio

(4)

(1) 2012 sales from chemical products exposed to patent expiry in the U.S., Japan and Western Europe over 2012/2015

(2) Based on 2015 internal estimates

(3) Over 2012-2015 (4) Dividend paid in 2014

~6%

50% of 2013 results

18

38-40%

Rebounding





> Sales CAGR

At least 5%

60

Q&A SESSION

APPENDICES

R&D Pipeline

63

Late Stage Pipeline –

Pharma & Vaccines

N New Molecular Entity G Genzyme

Central Nervous System Genetic diseases Oncology Metabolic Disorders Vaccines Internal Medicine

Registration

Phase III

Biosurgery

* ORIGIN: Evaluation of Lantus®_{in reducing cardiovascular morbidity & mortality}

iniparib

(BSI-201) squamous NSCLC

MACI

® Cell-based treatment Articular cartilage defects

Quadracel

® Diphtheria, tetanus, pertussis

& polio vaccine; 4-6 y of age

Hexaxim

® DTP-HepB-Polio-Hib vaccine

aflibercept

VEGF-Trap 1st _{line AIPC}

otamixaban

Direct Xa inhibitor ACS

Fluzone

®

_{& VaxiGrip}

®

_{QIV IM}

Quadrivalent inactivated

influenza vaccines

Plavix

® clopidogrel bisulfate PAD, STEMI, Japan

ombrabulin

(AV88E8062)

Vascular disrupting agent Sarcoma

Lantus

® insulin glargine ORIGIN*

Dengue

Mild-to-severe dengue fever vaccine

semuloparin

(AVE5026)

Indirect Xa/IIa inhibitor VTE prevention in cancer patients

Clolar

®

_{/ Evoltra}

® Purine nucleoside analog Adult acute myeloid leukemia (AML)

lixisenatide

(AVE0010)

GLP-1 agonist Type 2 diabetes

DTP-HepB-Polio-Hib

Pediatric hexavalent vaccine

teriflunomide

Relapsing forms of multiple sclerosis (RMS) –monotherapy, U.S. / EU

SAR302503

(TG101348)

JAK-2 inhibitor Myelofibrosis

New formulation

Insulin glargine Type 1+2 diabetes

Allegra

® fexofenadine Dry syrup, Japan

mipomersen

Apolipoprotein B-100 antisense hoFH and severe heFH, EU

teriflunomide

Multiple sclerosis

(monotherapy, adjunct therapy & CIS)

mipomersen

Apolipoprotein B-100 antisense hoFH (U.S.)

sarilumab

(SAR153191)

Anti-IL-6R mAb RA

lixisenatide

(AVE0010)

GLP-1 agonist Type 2 diabetes, EU

alemtuzumab

Anti-CD52 mAb Multiple sclerosis

eliglustat tartrate

Glucosylceramide synthetase inhibitor Gaucher disease

Lantus

® insulin glargine Pediatric, EU

aflibercept

VEGF-Trap 2nd_{line mCRC, U.S. / EU} N G G N N N N N G N G Thrombosis N G N 63 N G N

64

Early Stage Pipeline –

Pharma & Vaccines

N New Molecular Entity G Genzyme

Central Nervous System Oncology Metabolic Disorders Vaccines Internal Medicine

Phase II

Ophthalmology

iniparib

(BSI-201)

Ovarian cancer, non-squamous NSCLC, neoadjuvant breast cancer

FOV1101

FDC prednisolone/ cyclosporine Allergic conjunctivitis

SAR113945

IKK-βinhibitor Osteoarthritis

SAR3419

Maytansin-loaded anti-CD19 mAb B-cell malignancies (DLBCL, ALL)

safotibant

(FOV2304)

Bradykinin B1 antagonist Diabetic macular edema

SAR231893

Anti-IL4 mAb Asthma; Atopic dermatitis

SAR256212

(MM-121)

anti-ErbB3 mAb Breast cancer, NSCLC

SAR164877

Anti-NGF mAb Pain (on clinical hold)

ferroquine

Antimalarial Malaria

SAR245408

(XL147)

Oral PI3K inhibitor Endometrial cancer, Breast cancer

SAR110894

H3 antagonist Alzheimer's disease

fresolimumab

TGFβantagonist Fibrosis

SAR245409

(XL765)

Oral dual inhibitor of PI3K & mTOR Breast cancer, NHL

ACAM-Cdiff

Clostridium difficile Toxoid vaccine

SAR97276

Antimalarial Malaria

ombrabulin

(AVE8062)

Vascular disrupting agent Ovarian 2nd_{line, NSCLC 1}st_line

Rabies VRVg

Purified vero rabies vaccine

SAR279356

(F598)

Anti-PNAG mAb Seriousinfections

SAR302503

(TG101348)

JAK-2 inhibitor Polycythemia vera

Meninge ACYW conj.

2nd_{generation meningococcal} Conjugate infant vaccine

SAR236553

(REGN727)

Anti-PCSK-9 mAb Hypercholesterolemia N N N N N N N N N N G N 64 N N N N

65

Early Stage Pipeline –

Pharma & Vaccines

Phase I

SAR153192

Anti-DLL4 mAb Solid tumors

Genz644282

Topoisomerase-1 inhibitor Solid tumors

Gene therapy

(AAV-AADC)

Parkinson's disease

Rotavirus

Live Attenuated Tetravalent Rotavirus oral vaccine

SAR256212

(MM-121)

anti-ErbB3 mAb Ovarian cancer

Mozobil

®

_(plerixafor)

CXCR4 Antagonist AML

Acid sphingomyelinase

Niemann-Pick type B

Streptococcus pneumonia

Meningitis & pneumonia vaccine

SAR650984

Anti-CD38 naked mAb Hematological malignancies

GC1008

Anti-TGFβmAb Solid tumors

SAR339658

VLA 2 antagonist Inflammatory Bowel disease

Pseudomonas aeruginosa

Antibody fragment product Prevention of ventilator-associated pneumonia

SAR302503

(TG101348)

JAK-2 inhibitor Incyte resistant MF

Oral clofaribine

Purine nucleoside analog Myelodysplastic syndrome

SAR292833

(GRC15300)

TRPV3 antagonist Neuropathic pain, osteoarthritic pain

Tuberculosis

Recombinant subunit vaccine

SAR566658

Maytansin-loaded anti-DS6 DS6 positive solid tumors

SAR407899

Rho kinase inhibitor Diabetic nephropathy

SAR100842

LPA-1/LPA-3

Skin manifestation of scleroderma

RetinoStat

® Gene therapy

Wet age-related macular degeneration (AMD)

SAR307746

(REGN910)

Anti-Ang2 mAb Solid tumors

lixisenatide + Lantus

® GLP-1 agonist + insulin glargine Single pen device / Type 2 diabetes

SAR156597

IL4/IL13 Bi-specific mAb Idiopathic Pulmonary Fibrosis

StarGen

® Gene therapy Stargardt disease

SAR125844

M

et kinase inhibitor Solid tumors

SAR164653

Cathepsin A inhibitor

CV-related complications & deaths in diabetic patients

SAR114137

Cathepsin S/K inhibitor OA pain & Peripheral neuropathic pain

Gene therapy

(sFLT-01)

Age related Macular Degeneration (AMD) Combinations SAR245408 / MSC1936369B SAR245409 / MSC1936369B

SAR126119

TAFIa inhibitor Acute ischemic stroke

SAR411298

FAAH inhibitor Cancer pain N N N N N N G G N N G G

N New Molecular Entity G Genzyme

Central Nervous System Genetic diseases Oncology Metabolic Disorders Vaccines Internal Medicine Thrombosis Ophthalmology N N N N N N N N N G G N N G 65 N N